醫師調查：製藥公司排名堪稱一流，但並非盡善盡美

醫師並非獨自做出治療決策。他們依賴與同事的討論、最新的臨床研究以及包括製藥公司在內的可靠資訊來源。醫學事務團隊致力於透過提供合適的內容來滿足他們的需求。

了解醫生從哪裡獲取資訊、他們如何評估所接收資訊的品質以及他們獲取資訊的習慣，是醫學事務專業人員了解醫生真實需求的關鍵。

為了撰寫本報告，我們調查了法國、德國、義大利、西班牙、英國和美國的 426 位醫生，以了解他們對製藥公司如何滿足其醫療資訊需求和偏好的看法。醫生從事五個專業：心臟科（n=135）、內分泌學（n=53）、神經病學（n=90）、腫瘤學（n=98）和風濕病學（n=50）。

關鍵問題解答

• 1. 整體而言，您對目前取得藥物治療和疾病資訊的途徑滿意嗎？
• 2. 與其他來源相比，您多久會將製藥公司作為您獲取藥物和疾病資訊的首選？
• 3. 您認為製藥公司提供的藥物和疾病資訊的可信度如何？
• 4. 製藥公司提供的藥物和疾病資訊與您的需求和興趣有多相關？
• 5. 您認為您從製藥公司獲得的藥物和疾病資訊的及時性如何？

Physicians don't make treatment decisions on their own. They rely on discussions with colleagues, the latest clinical research and trusted sources - including pharma - to inform them. Medical affairs teams seek to meet doctors' needs by delivering tailored, relevant content.

Determining where physicians go for answers, how they gauge the quality of the information they receive and their habits when it comes to consuming it is key to helping medical affairs professionals get to the heart of what doctors want and need.

To help shed light on this, FirstWord polled 426 physicians from France, Germany, Italy, Spain, the UK, and the US to gather their views on how well pharma is meeting their medical information needs and preferences. The doctors work across five specialties: cardiology (n = 135), endocrinology (n = 53), neurology (n = 90), oncology (n = 98), and rheumatology (n = 50).

Key Questions Answered:

• 1. How satisfied are you overall, with your current access to information relating to drug treatments and disease?
• 2. Please indicate how often pharmaceutical companies are your first choice for accessing drug and disease information versus other sources.
• 3. How reliable do you consider the drug and disease information that comes from pharmaceutical companies?
• 4. How relevant to your needs/interests is the drug and disease information that comes from pharmaceutical companies?
• 5. How timely is the drug and disease information that comes from pharmaceutical companies?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.